An estimated one in five Americans live with chronic pain and current treatment options leave much to be desired.
Calliditas inches closer to full approval for IgA nephropathy drug – Pharmaceutical Technology
IgA nephropathy is a kidney disorder that causes inflammation. The US Food and Drug Administration (FDA) has granted Calliditas Therapeutics’ immunoglobulin A (IgA) nephropathy (IgAN)